Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma
Multiple MyelomaThis is a single patient protocol for TNB-383B in a subject with relapsed/refractory multiple myeloma (MM) who is not a candidate for treatment regimens known to provide clinical benefit in MM.
Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma
Multiple MyelomaThis is an individual patient, expanded access protocol using Selinexor and dexamethasone ("Sd") for the treatment of Relapsed, Refractory multiple myeloma in a 64 year old male, "19023-UMN-01" weighing 105.7 kg. 19023-UMN-01 has IgG kappa myeloma that has relapsed after numerous treatments.
Expanded Access Treatment Protocol CA204-143
Multiple MyelomaThe objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S. sites where licensed physicians determine clinical need.
This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor...
Non-Hodgkin's LymphomaHodgkin's Disease1 moreThe purpose of this program is to provide expanded access to plerixafor for patients with NHL, HD, or MM who are to receive treatment with an autologous peripheral stem cell transplant.
Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric...
Multiple MyelomaThe purpose of this individual-patient investigational new drug (IND) single patient request (SPR) is to provide participants treatment with JNJ-68284528, an investigational product prior to its marketing authorization. Such access may be considered for participants with serious/life-threatening diseases or conditions, where there exists no alternative treatments or where alternative treatments have been exhausted.
Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of...
Multiple Myeloma in RelapseMultiple MyelomaParticipant that has been diagnosed with Relapsed/ Refractory Multiple Myeloma and are currently participating in a clinical trial which is closing. This research study is studying Ulocuplumab as a possible treatment. It's an expanded access from NCT01359657
UARK 2009-32 Compassionate Use Study of Carfilzomib
Multiple MyelomaThis is a compassionate use, open-label, IND study for the purpose of providing carfilzomib to patients with relapsed or resistant refractory multiple myeloma.
Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed...
Multiple MyelomaTo provide pomalidomide access to relapsed/refractory multiple myeloma subjects with a likelihood of benefit from the pomalidomide treatment while the medication is not commercially available
A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE
Multiple MyelomaThe purpose of this study is to give patients who have had 4 or more prior lines of therapy for multiple myeloma access to VELCADE. The study is for patients who are not eligible for other clinical trials with VELCADE and for who VELCADE would otherwise not be available.
"FU-IFM2009" Database Post IFM/DFCI 2009 Study
Multiple MyelomaExtension of patient follow-up of the IFM/DFCI 2009 study over a period of 4 years (that is, from 01 December 2016 to 30 November 2020) during which patients will be followed up in the normal course of care and according to the usual care of the centers, with collection of the needed data about twice a year by the investigators